Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology

Petar M. Seferovic*, Gabriele Fragasso, Mark Petrie, Wilfried Mullens, Roberto Ferrari, Thomas Thum, Johann Bauersachs, Stefan D. Anker, Robin Ray, Yuksel Cavusoglu, Marija Polovina, Marco Metra, Giuseppe Ambrosio, Krishna Prasad, Jelena Seferovic, Pardeep S. Jhund, Giuseppe Dattilo, Jelena Celutkiene, Massimo Piepoli, Brenda MouraOvidiu Chioncel, Tuvia Ben Gal, Stefan Heymans, Rudolf A. de Boer, Tiny Jaarsma, Loreena Hill, Yuri Lopatin, Alexander R. Lyon, Piotr Ponikowski, Mitja Lainscak, Ewa Jankowska, Christian Mueller, Francesco Cosentino, Lars Lund, Gerasimos S. Filippatos, Frank Ruschitzka, Andrew J. S. Coats, Giuseppe M. C. Rosano

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1495-1503
Number of pages9
JournalEuropean journal of heart failure
Volume22
Issue number9
DOIs
Publication statusPublished - Sep 2020

Keywords

  • Heart failure
  • Sodium-glucose co-transporter 2 inhibitors
  • Type 2 diabetes mellitus
  • Cardiovascular outcomes
  • Quality of life
  • SERUM URIC-ACID
  • CARDIOVASCULAR OUTCOMES
  • SGLT2 INHIBITORS
  • DIABETES-MELLITUS
  • KIDNEY-DISEASE
  • EMPAGLIFLOZIN
  • DAPAGLIFLOZIN
  • RESISTANCE
  • RATIONALE
  • MORTALITY

Cite this